Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Assets Average: 2014-2025

Historic Assets Average for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $478.0 million.

  • Coherus Oncology's Assets Average fell 18.97% to $478.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478.0 million, marking a year-over-year decrease of 18.97%. This contributed to the annual value of $539.1 million for FY2024, which is 2.91% down from last year.
  • Coherus Oncology's Assets Average amounted to $478.0 million in Q3 2025, which was up 17.95% from $405.3 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Assets Average ranged from a high of $767.5 million in Q1 2021 and a low of $405.3 million during Q2 2025.
  • For the 3-year period, Coherus Oncology's Assets Average averaged around $526.0 million, with its median value being $478.0 million (2025).
  • Its Assets Average has fluctuated over the past 5 years, first surged by 75.33% in 2021, then slumped by 43.65% in 2025.
  • Over the past 5 years, Coherus Oncology's Assets Average (Quarterly) stood at $710.5 million in 2021, then decreased by 27.40% to $515.9 million in 2022, then rose by 17.60% to $606.7 million in 2023, then dropped by 21.42% to $476.8 million in 2024, then dropped by 18.97% to $478.0 million in 2025.
  • Its last three reported values are $478.0 million in Q3 2025, $405.3 million for Q2 2025, and $409.8 million during Q1 2025.